EUVIMEDEUVIMED entdecken
Crossref

Effectiveness and safety of once‐daily tacrolimus formulations in de novo liver transplant recipients: The PRETHI study

Itxarone Bilbao iD, Miguel Ángel Gómez Bravo, Alejandra Otero iD, Laura Lladó, José Luís Montero, Luisa González Dieguez, Javier Graus, José Antonio Pons Miñano

Clinical Transplantation · 2023

DOI: 10.1111/ctr.15105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Transplantation, 2023. Verfasst von Itxarone Bilbao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Cirugía Hepatobiliopancreática y Trasplantes Digestivos, Hospital Universitario Vall d'Hebron, VHIR, Universidad Autónoma de Barcelona, B…. Hauptthemen laut MEDLINE: Liver Transplantation, Kidney Transplantation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Chiesi España S.A.U.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Data comparing long‐term effectiveness and safety of once‐daily tacrolimus formulations in de novo liver transplantation are scarce. We compared the effectiveness, pharmacokinetic profile, and safety of LCPT (Envarsus) and PR‐Tac (Advagraf) for up to 12 months post‐transplant. Adult de novo liver transplant recipients who started IR‐Tac (Prograf) and were converted to LCPT or PR‐Tac 3–5 days post‐transplant were included. Data from 163 patients were analyzed, 87 treated with LCPT and 76 with PR‐Tac. The incidence of treatment failure was 30.5% in the LCPT group versus 23.0% in the PR‐Tac group ( p = .291). Biopsy‐proven acute rejection (BPAR) was reported in 26.8% of patients in the LCPT group and 17.6% in the PR‐Tac group ( p = .166). Graft loss was experienced in one patient (1.2%) in the LCPT group and three patients (4.1%) in the PR‐Tac group ( p = .346). Death was registered in three patients (3.7%) in the LCPT group and three patients (4.1%) in the PR‐Tac group ( p > .999). Patients in the LCPT group showed 45.7% higher relative bioavailability (C min /total daily dose [TDD]; p < .01) with similar C min and 33.3% lower TDD versus PR‐Tac ( p < .01). The evolution of renal function, safety profile, and the incidence of post‐transplant renal failure, dyslipidemia, obesity, hypertension, and diabetes mellitus were similar in patients treated with LCPT and PR‐Tac. In de novo liver transplant patients, LCPT and PR‐Tac showed comparable effectiveness with higher relative bioavailability, similar C min and lower TDD in the LCPT group. Renal function, safety, and post‐transplant complications were comparable in LCPT and PR‐Tac groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationKidney TransplantationAdultHumansTacrolimusImmunosuppressive AgentsDrug Administration ScheduleProspective StudiesGraft RejectionTransplant Recipients

Stichwörter der Autor:innen

liver transplantpharmacokineticssafetytacrolimustreatment failure

Substanzen

TacrolimusImmunosuppressive Agents

Autor:innen und Institutionen

  • Servicio de Cirugía Hepatobiliopancreática y Trasplantes Digestivos, Hospital Universitario Vall d'Hebron, VHIR, Universidad Autónoma de Barcelona, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain.
  • Hospital Virgen del Rocío, Sevilla, Spain.
  • Hospital de A Coruña, A Coruña, Spain.
  • Hospital U Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.
  • Unidad de hepatología, Hospital U Reina Sofía, Córdoba, Spain.

ORCID-Profile: Itxarone Bilbao, Alejandra Otero

Förderung

  • Chiesi España S.A.U

Zitieren

APA

Bilbao, I., Gómez Bravo, M. Á., Otero, A., Lladó, L., Montero, J. L., González Dieguez, L., Graus, J., & Pons Miñano, J. A. (2023). Effectiveness and safety of once‐daily tacrolimus formulations in de novo liver transplant recipients: The PRETHI study. Clinical Transplantation. https://doi.org/10.1111/ctr.15105

Vancouver

Bilbao I, Gómez Bravo MÁ, Otero A, Lladó L, Montero JL, González Dieguez L, et al. Effectiveness and safety of once‐daily tacrolimus formulations in de novo liver transplant recipients: The PRETHI study. Clinical Transplantation. 2023. doi:10.1111/ctr.15105

BibTeX
@article{Bilbao2023,
  author = {Bilbao, Itxarone and Gómez Bravo, Miguel Ángel and Otero, Alejandra and Lladó, Laura and Montero, José Luís and González Dieguez, Luisa and Graus, Javier and Pons Miñano, José Antonio},
  title = {Effectiveness and safety of once‐daily tacrolimus formulations in de novo liver transplant recipients: The PRETHI study},
  journal = {Clinical Transplantation},
  year = {2023},
  doi = {10.1111/ctr.15105}
}
Kostenlos starten →